Mucopexy Versus Laser Hemorrhoidoplasty for the Treatment of Hemorrhoidal Disease (MuLa)
Primary Purpose
Hemorrhoids
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
laser hemorrhoidoplasty
mucopexy
Sponsored by
About this trial
This is an interventional treatment trial for Hemorrhoids
Eligibility Criteria
Inclusion Criteria:
- Informed Consent as documented by signature
- Hemorrhoidal disease grade II to III unresponsive to medical therapy
- Age ≥18
Exclusion Criteria:
- Inability to follow the procedures of the study,
- Enrollment of the investigator, his/her family members, employees and other dependent persons,
- Anesthesiology contraindications to surgery,
- Emergency situation,
- Hemorrhoids associated with pregnancy,
- Oher surgical intervention performed at the same time of the hemorrhoids treatment,
- Concomitant anorectal disorders (fissure, fistula), thrombosed hemorrhoid,
- Previous pelvic radiotherapy, previous proctologic intervention during the last three months.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
The laser hemorrhoidoplasty (laser group, intervention group)
The hemorrhoidopexy (mucopexy group, control group)
Arm Description
Outcomes
Primary Outcome Measures
The Symptom Score
The primary outcome will be the "Symptom Score" at six postoperative months. This score ranges from 0 to 15 points, based on each of the five cardinal symptoms of hemorrhoidal disease (pain, itching, bleeding, discharge and prolapse) attributed from 0 to 3 points according to the frequency of their manifestation (0 point: never, 1 point: > 1x/month, <1x/week, 2 points: 1-6x/week, 3 points: 1x/day).
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04881344
Brief Title
Mucopexy Versus Laser Hemorrhoidoplasty for the Treatment of Hemorrhoidal Disease
Acronym
MuLa
Official Title
Mucopexy Versus Laser Hemorrhoidoplasty for the Treatment of Hemorrhoidal Disease, a Prospective Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Unknown status
Study Start Date
June 2021 (Anticipated)
Primary Completion Date
July 2022 (Anticipated)
Study Completion Date
December 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Ris Frederic
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Hemorrhoidal disease is a frequent anorectal disorder and the main reason for a visit to a coloproctologist. Hemorrhoids are present in healthy individuals. However, they can become pathologic, manifesting with pain, prolapse, itching, bleeding or soiling. Initially, they can be managed conservatively. When this failed to cure the symptoms, surgical therapy is indicated. For grade II (hemorrhoids prolapsing during straining but reducing spontaneously) or grade III (hemorrhoids prolapsing during straining but requiring manual reduction), laser hemorrhoidoplasty or mucopexy are safe and efficient procedures to treat hemorrhoids. However, the optimal treatment is still under debate. Recently, a randomized controlled trial reported lower recurrence and faster return to work associated with laser therapy. We aimed to compare both therapies, to assess the benefits of laser therapy for the treatment of hemorrhoidal disease symptoms, using a validated score.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemorrhoids
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
42 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
The laser hemorrhoidoplasty (laser group, intervention group)
Arm Type
Experimental
Arm Title
The hemorrhoidopexy (mucopexy group, control group)
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
laser hemorrhoidoplasty
Intervention Description
Under local anesthetic (or general anesthetic if contraindications to local anesthetic),
A laser optic fiber connected to a diode platform (Leonardo, Biolitec AG, Jena, Germany) will be applied threw a anoscope. After making a 1-mm opening at the external border of hemorrhoid pocket, the fiber will be introduced in the hemorrhoidal tissue. Several pulses, each lasting for 1.2 s, with a 0.6-s pause between pulses, will be delivered to the tissue.
As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention),
Postoperative care will consist of: normal diet, bulking laxatives, self-irrigation to the anal wound at six times per day and painkiller. Absence for work certificate will be made for 7 days for each patient and they will be told to return to work and normal daily activities as soon as they felt able.
Intervention Type
Procedure
Intervention Name(s)
mucopexy
Intervention Description
Threw an anoscope, the hemorrhoidal cushion will be sutured using a half-circle (size 26) needle with a 2-0 poliglecaprone (Monocryl®, Ethicon, USA). Then, a continuous suture will be performed on the mucosa of the anal canal, and will terminate above the dentate line. The hemorrhoidal artery will be ligated by this suture. Then, the ligation will be tied to realize the hemorrhoidopexy.
Same anesthetic technique and postoperative care as the intervention group. As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention).
Primary Outcome Measure Information:
Title
The Symptom Score
Description
The primary outcome will be the "Symptom Score" at six postoperative months. This score ranges from 0 to 15 points, based on each of the five cardinal symptoms of hemorrhoidal disease (pain, itching, bleeding, discharge and prolapse) attributed from 0 to 3 points according to the frequency of their manifestation (0 point: never, 1 point: > 1x/month, <1x/week, 2 points: 1-6x/week, 3 points: 1x/day).
Time Frame
6 postoperative months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Informed Consent as documented by signature
Hemorrhoidal disease grade II to III unresponsive to medical therapy
Age ≥18
Exclusion Criteria:
Inability to follow the procedures of the study,
Enrollment of the investigator, his/her family members, employees and other dependent persons,
Anesthesiology contraindications to surgery,
Emergency situation,
Hemorrhoids associated with pregnancy,
Oher surgical intervention performed at the same time of the hemorrhoids treatment,
Concomitant anorectal disorders (fissure, fistula), thrombosed hemorrhoid,
Previous pelvic radiotherapy, previous proctologic intervention during the last three months.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gregoire Longchamp, M.D.
Phone
+41795530226
Email
gregoire.longchamp@hcuge.ch
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Mucopexy Versus Laser Hemorrhoidoplasty for the Treatment of Hemorrhoidal Disease
We'll reach out to this number within 24 hrs